Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a stable dose of one of the following for at least 3 months prior to screening: \* \>=1000 mg/day immediate-release metformin; or metformin \>=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy.~* HbA1c between 7.1% and 11.0%, inclusive.~* Body Mass Index (BMI) \>21 kg/m\^2 and \<35 kg/m\^2.~Exclusion Criteria:~* Have participated in this study previously, or any other study using exenatide or GLP-1 analogs.~* Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening.~* Have characteristics contraindicating metformin or sulfonylurea use.~* Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening.~* Have used drugs for weight loss within 1 month of screening.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in volume equal to exenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).